How to get your high-risk patients to the new NCEP goals.
Now that the optimal LDL-cholesterol level for patients with coronary heart disease or its risk equivalents is substantially below 100 mg/dL consider aggressive lipid-lowering strategies in this group. With the advent of more powerful statins, combination therapy, and newer nonstatin agents, you can...
| Publicado en: | Patient Care (Print) Vol. 40; no. 2; pp. 26 - 35 |
|---|---|
| Autor principal: | |
| Formato: | case study pictorial questionnaire/scale tables/charts Journal Article |
| Publicado: |
MJH Life Sciences
Feb2006
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Now that the optimal LDL-cholesterol level for patients with coronary heart disease or its risk equivalents is substantially below 100 mg/dL consider aggressive lipid-lowering strategies in this group. With the advent of more powerful statins, combination therapy, and newer nonstatin agents, you can help a significantly greater proportion of your patients attain their lipid goals. |
|---|